$Moderna, Inc.(MRNA)$ @Trade F

MRNA

12-03 04:55

USModerna, Inc.

Side	Price \| Filled	Realized P&L
Sell Close	24.10 150	-13.90% Closed

Moderna, Inc.

Trade Feed: Who is your favorite trader?

Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the "hidden gem traders" that you've discovered!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Trade Feed Decoder
12-03
Trade Feed Decoder
This Moderna (MRNA) sell at a 13.9% loss highlights challenges in timing growth-stage biotech investments. The vaccine producer faces declining COVID-related revenue (Q1 2024 sales fell 91% YoY), potentially driving bearish sentiment. While the loss suggests possible entry during pandemic-era optimism, the exit reflects recognition of evolving market dynamics - Moderna's non-COVID pipeline remains preclinical with 2025 commercialization targets. The trade underscores the volatility of single-stock biotech positions, where binary pipeline outcomes and shifting therapeutic demand create asymmetric risk. Investors might consider whether portfolio sizing accounted for Moderna's transition phase between COVID windfalls and unproven mRNA initiatives. The execution aligns with cutting losses amid uncertainty, though sector-focused traders might monitor RSV/mRNA flu vaccine adoption as potential catalysts.

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":506622624477624,"tweetId":"506622624477624","gmtCreate":1764708970427,"gmtModify":1764708973703,"author":{"id":4109843165472380,"idStr":"4109843165472380","authorId":4109843165472380,"authorIdStr":"4109843165472380","name":"Mic6226","avatar":"https://community-static.tradeup.com/news/642ea3ba3ea408756b94df1fc4fc2d69","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.28","exceedPercentage":"93.30%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":54,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":25,"starInvestorOrderShareNum":196,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":-25.02,"showRor":true,"winRationPercentage":72.114137,"tradeVolumeEst":0},"themes":[{"themeId":"4e1ab37448a24dd39b7882426fc6fd27","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"Trade Feed: Who is your favorite trader?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":4e1ab37448a24dd39b7882426fc6fd27}&rnconfig={\"headerBarHidden\": true}","description":"Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the \"hidden gem traders\" that you've discovered!","image":"https://community-static.tradeup.com/news/e496e574dd744490c7b4f7959f83f5a4"}],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","text":"$Moderna, Inc.(MRNA)$ @Trade Feed Decoder","highlighted":1,"essential":1,"paper":1,"likeSize":37,"commentSize":1,"repostSize":14,"favoriteSize":0,"link":"https://ttm.financial/post/506622624477624","repostId":0,"isVote":1,"tweetType":1,"viewCount":940,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MRNA"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"4109843165472380","orderId":"41393814396469248","kind":"TRADE","symbol":"MRNA","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/MRNA","symbolName":"Moderna, Inc.","market":"US","action":"SELL","currency":"USD","symbolLogo":"https://static.tigerbbs.com/14616184bdf9319c4f99d33f15d3ec0d","showFilledQuantity":true,"nameCN":"Moderna, Inc.","orderType":"LMT","filledQuantityFinal":150,"avgFillPrice":24.1,"createTime":1764708941,"filledQuantity":"150","filledQuantityScale":"0","openFlag":false,"side":"DEBIT","contractMajorDescription":"Moderna, Inc.","contractExtraDescription":"MRNA","legs":[],"completedFlag":true,"orderPnl":{"realizedPnlPercent":-0.139,"realizedPnlByAveragePercent":-0.1077},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖","未分享订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":506645860254328,"commentId":"506645860254328","gmtCreate":1764714640367,"gmtModify":1764725735424,"authorId":10000000000011060,"author":{"id":10000000000011060,"idStr":"10000000000011061","authorId":10000000000011060,"name":"Trade Feed Decoder","avatar":"https://community-static.tradeup.com/news/4dc8fec78bad5acffbf563bdbc6bc8ed","vip":4,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":506622624477624,"objectIdStr":"506622624477624","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"This Moderna (MRNA) sell at a 13.9% loss highlights challenges in timing growth-stage biotech investments. The vaccine producer faces declining COVID-related revenue (Q1 2024 sales fell 91% YoY), potentially driving bearish sentiment. While the loss suggests possible entry during pandemic-era optimism, the exit reflects recognition of evolving market dynamics - Moderna's non-COVID pipeline remains preclinical with 2025 commercialization targets. The trade underscores the volatility of single-stock biotech positions, where binary pipeline outcomes and shifting therapeutic demand create asymmetric risk. Investors might consider whether portfolio sizing accounted for Moderna's transition phase between COVID windfalls and unproven mRNA initiatives. The execution aligns with cutting losses amid uncertainty, though sector-focused traders might monitor RSV/mRNA flu vaccine adoption as potential catalysts.","text":"This Moderna (MRNA) sell at a 13.9% loss highlights challenges in timing growth-stage biotech investments. The vaccine producer faces declining COVID-related revenue (Q1 2024 sales fell 91% YoY), potentially driving bearish sentiment. While the loss suggests possible entry during pandemic-era optimism, the exit reflects recognition of evolving market dynamics - Moderna's non-COVID pipeline remains preclinical with 2025 commercialization targets. The trade underscores the volatility of single-stock biotech positions, where binary pipeline outcomes and shifting therapeutic demand create asymmetric risk. Investors might consider whether portfolio sizing accounted for Moderna's transition phase between COVID windfalls and unproven mRNA initiatives. The execution aligns with cutting losses amid uncertainty, though sector-focused traders might monitor RSV/mRNA flu vaccine adoption as potential catalysts.","html":"This Moderna (MRNA) sell at a 13.9% loss highlights challenges in timing growth-stage biotech investments. The vaccine producer faces declining COVID-related revenue (Q1 2024 sales fell 91% YoY), potentially driving bearish sentiment. While the loss suggests possible entry during pandemic-era optimism, the exit reflects recognition of evolving market dynamics - Moderna's non-COVID pipeline remains preclinical with 2025 commercialization targets. The trade underscores the volatility of single-stock biotech positions, where binary pipeline outcomes and shifting therapeutic demand create asymmetric risk. Investors might consider whether portfolio sizing accounted for Moderna's transition phase between COVID windfalls and unproven mRNA initiatives. The execution aligns with cutting losses amid uncertainty, though sector-focused traders might monitor RSV/mRNA flu vaccine adoption as potential catalysts.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerFlag":true,"disclaimerType":1,"specialCommentTag":"AI_ANALYSE"}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/506622624477624"}